Sodium nitroprusside treatment for psychotic symptoms and cognitive deficits of schizophrenia: A randomized, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Sodium nitroprusside treatment for psychotic symptoms and cognitive deficits of schizophrenia: A randomized, double-blind, placebo-controlled trial

Published:2018-11 Issue: Volume:269 Page:271-277
ISSN:0165-1781
Container-title:Psychiatry Research
language:en
Short-container-title:Psychiatry Research

Author:

Wang Xiujuan,Zhao Jingyuan,Hu YunQing,Jiao Zhiqiang,Lu Yanli,Ding Minli,Kou Yanna,Li Benliang,Meng Fancui,Zhao Hongzu,Li Hong,Li Wenqiang,Yang Yongfeng,Lv Luxian

Funder

National Natural Science Foundation of China

Fundamental and Advancing Foundation of Henan Province

Open Program of Henan Key Laboratory of Biological Psychiatry

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference40 articles.

1. Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia;Aoyama;Br. J. Psychiatry,2011

2. Cognitive impairment in schizophrenia: the great unmet need;Aquila;CNS Spectr.,2015

3. Blockade of phencyclidine-induced effects by a nitric oxide donor;Bujas-Bobanovic;Br. J. Pharmacol.,2000

4. Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla;Bustillo;Biol. Psychiatry,2011

5. Cascading and combined effects of cognitive deficits and residual symptoms on functional outcome in schizophrenia—a path-analytical approach;Bhagyavathi;Psychiatry Res.,2015

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of sodium nitroprusside in the treatment of drug-naive subjects in first episode psychosis - An open label study;Schizophrenia Research;2024-07

2. The Impact of LY487379 or CDPPB on eNOS Expression in the Mouse Brain and the Effect of Joint Administration of Compounds with NO• Releasers on MK-801- or Scopolamine-Driven Cognitive Dysfunction in Mice;Molecules;2024-01-29

3. The efficacy and safety of sodium nitroprusside in the treatment of schizophrenia: a meta-analysis;Frontiers in Psychiatry;2023-11-06

4. Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review;Neuropsychopharmacology Reports;2023-10-04

5. The Nitric Oxide (NO) Donor Molsidomine Counteract Social Withdrawal and Cognition Deficits Induced by Blockade of the NMDA Receptor in the Rat;International Journal of Molecular Sciences;2023-04-06